The Dorothy Bullock Memorial

National Diabetes Center©

The National Heart, Lung, and Blood Institute (NHLBI) and
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
of the National Institutes of Health (NIH)
have collaborated with three leading private health organizations
on a major public health statement
to alert physicians, patients, and the general public to the
increasing significance of diabetes mellitus as a
major risk factor for cardiovascular disease
(
v.o. G.U.T. of Diabetic Complications)

Site Map
Home

The Diabetes Daily News©
Conceptual News Index
Friday, October 27, 2006 10:30:02 -0400
Type 1 Diabetes
Monitoring
Patho
Rx
Type 2 Diabetes
Monitoring
Nutrition
Patho
Rx
Microvascular Complications
General
Nephropathy
Neuropathy
Retinopathy
*Atherosis
Patho
Rx
Type 1 Information
Stats HbA1c Info Pump Insulin
Type 2 Guidelines
Rx
SFU
BGN
TZD
Lipids
Safety Slideshow



[Slides]
ADA Hospital Admission Guidelines
Control Other
   
 
This non-invasive glucose-monitoring device goes before an FDA Advisory Committee meeting on December 6th 1999. If approved the device could be on the market as early as April, 2000 [click on the watch for actual data]

Avandia™ Rejected by European Union Committee for Medicinal Products
(This decision may have been based mainly on cost-benefit considerations)
Landmark Type 2 Diabetes Study to Examine Effects of Early Treatment
With Avandia(R) (Rosiglitazone Maleate) on Disease Progression;
Worldwide, 4-Year Study to Enroll More Than 3,500 Newly Diagnosed
ISRAELI STUDY IS NOW THE FOURTH TO SHOW INCREASED MORTALITY WITH
METFORMIN- SULFONYLUREA COMBINATION THERAPY (Study#1/ Study#2/ Study#3)

NDC Magazine

CiteLine Award

| Contact Us | 

©1995-2001 The National Diabetes Center. All rights reserved. All information is intended for your general knowledge only and is not a substitute for medical advice or treatment for specific medical conditions.

Home Page
Reload The National Diabetes Center Frames